Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00650195 | Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg | PHASE1 | COMPLETED | 56 | — | — | Feb 1, 2004 | Mar 1, 2004 | Apr 24, 2024 | 1 | United States |
| NCT00649181 | Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg | PHASE1 | COMPLETED | 52 | — | — | Oct 1, 2003 | Nov 1, 2003 | Apr 24, 2024 | 1 | United States |
| NCT00649051 | Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg | PHASE1 | COMPLETED | 52 | — | — | Dec 1, 2002 | Jan 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Metolazone Tablets 10 mg |
| 2 | ACTIVE_COMPARATOR | Zaroloxyn® Tablets 10 mg |
| Name | Type | Description |
|---|---|---|
| Metolazone Tablets 10 mg | DRUG | 10mg, single dose fasting |
| Zaroloxyn® Tablets 10 mg | DRUG | 10mg, single dose fasting |
| Metolazone Tablets 5 mg | DRUG | 2x5mg, single dose fasting |
| Zaroloxyn® Tablets 5 mg | DRUG | 2x5mg, single dose fasting |
| Metolazone Tablets 2.5 mg | DRUG | 4x2.5mg, single dose fasting |
| Zaroloxyn® Tablets 2.5 mg | DRUG | 4x2.5mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum b-human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening pr...